Interview with Tomáš Matějovský, Partner, CMS Cameron McKenna Czech…
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Address: CMS Cameron McKenna v.o.s. Palladium, Na Poříčí 1079/3a 110 00 Prague 1,Czech Republic
Tel: +420 296 798-111
Web: http://www.cms-cmck.com/Prague-Czech-Republic
The Prague office of CMS was established in 1991. The office has over 35 international and local lawyers and provides a full range of legal services to both domestic and international clients. We conduct regular independent reviews with clients and these indicate that they value our ability to combine international expertise with local knowledge.
We have significant experience in working with international and local companies, insurers, banks and financial institutions, private organizations and government authorities. CMS in Prague is considered a market leader and our experts, such as Tomáš Matějovský, receive excellent feedback from clients.
CMS Cameron McKenna has a track record of advising lifesciences businesses throughout Central and Eastern Europe. We have been established in the region for more than twenty years, which means we never underestimate the differences between local markets, whilst taking into account EU and EEA standards.
Over the past years sector regulations in the region have undergone significant changes – from the rules on marketing pharmaceutical and healthcare products to legislation relating to medical devices. The changes have had a profound effect on the way business is conducted in CEE. We’ve made it our business to know the market inside out.
Our clients tell us that we have the in-depth knowledge they need to support their businesses across the region. We speak the industry’s language and our cross-regional lifesciences practice comprises 50+ lawyers advising some of the sector’s major players and representatives.
Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated…
Mr. Dvořáček, in 2010, the AIFP commissioned a study on the economic footprint of the innovative pharmaceutical industry in the Czech Republic. Can you begin by expounding the results of…
Mr. Kotek, can you please begin by introducing us to the SVOPL and telling us what the mission is here in the Czech Republic? We are a relatively new Association…
See our Cookie Privacy Policy Here